Pharmacogenomic Test

Preferred Label : Pharmacogenomic Test;

Alternative definition : FDA: An assay intended to study interindividual variations in whole-genome or candidate gene, single-nucleotide polymorphism (SNP) maps, haplotype markers, or alterations in gene expression or inactivation that may be correlated with pharmacological function and therapeutic response. In some cases, the pattern or profile of change is the relevant biomarker, rather than changes in individual markers.; CDISC-GLOSS: An assay intended to study interindividual variations in whole genome or candidate gene maps, biomarkers, and alterations in gene expression or inactivation that may be correlated with pharmacological function and therapeutic response. Compare to pharmacogenetic test.;

NCI Metathesaurus CUI : CL524166;

Details

Origin ID

C68762;

UMLS CUI

C2347501;

Automatic exact mappings (from CISMeF team)
- Pharmacogenomic Testing [MeSH concept]
- test pharmacogenomics [medical devices type]
CISMeF manual mappings
- Pharmacogenomic Testing [MeSH Descriptor]
Semantic type(s)
- Laboratory Procedure [UMLS semantic type]
UMLS correspondences (same concept)
- Pharmacogenomic Testing [MeSH Descriptor]
concept_is_in_subset
- CDISC Glossary Terminology [NCIt concept]
- CTRP Intervention Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- Clinical Data Interchange Standards Consortium Terminology [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients